Radequinil
Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Radequinil
Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.
has abstract
Radequinil (INN; AC-3933) is a ...... ted and it was never marketed.
@en
CAS number
219846-31-8
FDA UNII code
2G222T03EY
PubChem
Wikipage page ID
35,886,718
page length (characters) of wiki page
Wikipage revision ID
970,045,650
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
ChemSpiderID
11,584,471
IUPAC name
PubChem
22,714,308
SMILES
COc1ccccc3nccc2NC\Cc4ncon4
@en
StdInChIKey
JQOFKKWHXGQABB-UHFFFAOYSA-N
@en
wikiPageUsesTemplate
subject
hypernym
comment
Radequinil (INN; AC-3933) is a ...... ted and it was never marketed.
@en
label
Radequinil
@en